DENTSPLY SIRONA Inc. (XRAY) Form 10-Q — Nov 5, 2026
DENTSPLY SIRONA reported Q3 2026 net sales of $836 million, down from $904 million a year earlier, with a small net loss of $2 million and EPS of $(0.01). Revenue declined across all dental segments, with Orthodontic and Implant Solutions down 17% to $171 million, while Wellspect Healthcare grew to $92 million. In October 2026 the company obtained lender consents to amend its credit facility and note purchase agreements, raising maximum permitted leverage ratios and temporarily restricting new liens, subsidiary debt, and certain restricted payments.
Key figures
- Revenue
- 836
- Net Income
- -2
- Total Debt
- 2200
- Revenue Yoy
- -7.5%
- Total Assets
- 5190
- Cash Position
- 195
- Shares Outstanding
- 198153678
- Nine month eps
- 0.12
- Q3 2025 revenue
- 904
- Capex guidance 2026
- $165-185 million
- Q3 share repurchases
- 1.2 million shares at average $9.75 ($13 million)
- Securities settlement
- $75 million (funded by insurers)
- Nine month revenue 2026
- 2614
- Commercial paper outstanding
- 215
- Expected restructuring charges
- $60-65 million
- Expected annualized cost savings
- $100 million
- Restructuring charges incurred 2026 plan
- $54 million
- Share repurchase authorization remaining
- $1.2 billion
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.